ACADIA Pharmaceuticals (ACAD) Expected to Announce Quarterly Earnings on Tuesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is anticipated to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $277.65 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $20.04 on Tuesday. The stock has a 50 day moving average of $18.03 and a 200 day moving average of $16.67. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of 25.69 and a beta of 0.37. ACADIA Pharmaceuticals has a fifty-two week low of $14.15 and a fifty-two week high of $26.56.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ACAD shares. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.